IMNN Imunon Inc

Price (delayed)

$1.47

Market cap

$8.25M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.84

Enterprise value

$4.23M

?
Relative Growth: Rel. Growth: 20
Relative Strength: Rel. Strength: 6
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 5

Celsion is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies, and a platform for the development of nucleic ...

Highlights
Imunon's quick ratio has soared by 179% YoY and by 116% from the previous quarter
The company's EPS has surged by 68% YoY and by 30% QoQ

Key stats

What are the main financial stats of IMNN

IMNN stock price

How has the Imunon stock price performed over time
Intraday
-2.65%
1 week
4.26%
1 month
-10.37%
1 year
-71.23%
YTD
-61.42%
QTD
-17.42%

Financial performance

How have Imunon's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$14.84M
Net income
-$14.72M
Gross margin
N/A
Net margin
N/A
IMNN's operating income is up by 7% YoY
The net income has grown by 7% YoY

Price vs fundamentals

How does IMNN's price correlate with its fundamentals

Growth

What is Imunon's growth rate over time

Valuation

What is Imunon stock price valuation
P/E
N/A
P/B
1.47
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 68% YoY and by 30% QoQ
The equity has soared by 57% year-on-year and by 25% since the previous quarter
IMNN's price to book (P/B) is 53% lower than its 5-year quarterly average of 3.2 and 37% lower than its last 4 quarters average of 2.4

Efficiency

How efficient is Imunon business performance
IMNN's ROIC has soared by 93% QoQ
The ROE has grown by 22% YoY and by 8% from the previous quarter
Imunon's return on assets has increased by 16% YoY and by 13% QoQ

Dividends

What is IMNN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMNN.

Financial health

How did Imunon financials performed over time
The total assets is 39% more than the total liabilities
Imunon's quick ratio has soared by 179% YoY and by 116% from the previous quarter
The company's total liabilities has surged by 132% QoQ and by 76% YoY
IMNN's debt is 87% more than its equity
The equity has soared by 57% year-on-year and by 25% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.